MarketCap
Facebook
X
Telegram
TransMedics Group Financial Ratios 2025-2011 | TMDX
Brief overview of TransMedics Group's multiples and efficiency
This overview follows the five latest available observations from 2021 through 2025.
Market valuation is represented by P/S 7.75x (median 11.96x), P/B 9.92x (median 10.71x). Valuation is roughly 21.3% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
End-period return metrics are ROE 40.2%, ROA 17.8%, ROCE 23%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
Current PEG is 0.18x; the market pays comparatively little per unit of expected growth.
The cash conversion cycle decreased 345.7 days to 111.1 days, supporting working-capital efficiency.
Overall assessment
TransMedics Group combines solid capital returns with a discount to its own history. The main question is whether earnings and growth are sustainable.
Annual Financial Ratios TransMedics Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
24.7 | 69.0 | -115.6 | -61.4 | -9.9 | -19.6 | -8.4 | - | - | - | - | - | - | - | - |
P/S |
7.8 | 5.5 | 12.0 | 23.8 | 14.5 | 21.9 | 11.9 | - | - | - | - | - | - | - | - |
EPS |
5.6 | 1.1 | -0.8 | -1.2 | -1.6 | -1.2 | -2.4 | -17.5 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
4.8 B | 2.69 B | 3.06 B | 2.11 B | 480 M | 586 M | 311 M | 26.2 M | 206 M | - | - | - | - | - | - |
EBITDA per Share |
3.99 | 1.72 | -0.63 | -0.95 | -1.36 | -1 | -2 | - | - | - | - | - | - | - | - |
EV/EBITDA |
35.4 | 46.9 | -149.1 | -75.5 | -12.1 | -25.4 | -10.4 | - | - | - | - | - | - | - | - |
PEG |
-0.46 | -0.77 | - | - | - | -1.5 | 0.18 | - | - | - | - | - | - | - | - |
P/B |
9.9 | 10.7 | 21.1 | 11.9 | 6.5 | 5.4 | 5.1 | - | - | - | - | - | - | - | - |
P/CF |
24.3 | 50.2 | -221.8 | -48.5 | -15.2 | -18.6 | -8.6 | - | - | - | - | - | - | - | - |
ROE % |
40.22 | 15.53 | -18.22 | -19.32 | -65.16 | -27.67 | -61.39 | - | - | - | - | - | - | - | - |
ROA % |
17.81 | 4.42 | -3.54 | -13.06 | -32.78 | -18.91 | -31.86 | - | - | - | - | - | - | - | - |
ROCE % |
22.95 | 16.40 | -20.94 | -16.78 | -58.11 | -25.40 | -33.19 | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.4 | 1.2 | 3.1 | 2.0 | 3.2 | 6.2 | - | - | - | - | - | - | - | - |
DSO |
54.9 | 66.7 | 68.9 | 65.5 | 77.2 | 95.5 | 101.4 | - | - | - | - | - | - | - | - |
DIO |
71.8 | 92.3 | 135.2 | 229.6 | 537.2 | 469.2 | 420.3 | - | - | - | - | - | - | - | - |
DPO |
15.5 | 23.4 | 33.5 | 64.7 | 157.5 | 171.3 | 271.5 | - | - | - | - | - | - | - | - |
Operating Cycle |
126.6 | 159.0 | 204.1 | 295.1 | 614.3 | 564.8 | 521.7 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
111.1 | 135.6 | 170.6 | 230.4 | 456.8 | 393.4 | 250.1 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios TransMedics Group
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.42 | 0.21 | - | 0.71 | 1.03 | 0.76 | - | 0.13 | 0.37 | 0.37 | - | -0.78 | -0.03 | -0.08 | - | -0.25 | -0.41 | -0.38 | - | -0.47 | -0.39 | -0.29 | -0.23 | -0.19 | -0.36 | -0.42 | -0.43 | -0.39 | -0.7 | -4.86 | -5.48 | -3.73 | -1.3 | -3.61 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
1.33 | 0.73 | - | 1.26 | 1.08 | 1 | - | 0.12 | 0.38 | 0.51 | - | - | - | -0.02 | - | -0.11 | -0.35 | -0.32 | - | -0.37 | -0.36 | -0.22 | -0.22 | -0.13 | -0.31 | -0.36 | -0.41 | -0.3 | -0.55 | -4.03 | -4.55 | -2.48 | -1.03 | -3.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
22.13 | 28.94 | 27.46 | 29.47 | 29.05 | 25.72 | 16.08 | -4.02 | -6.72 | -14.51 | -22.16 | -26.11 | -28.64 | -45.58 | -44.21 | -60.71 | -68.75 | -54.23 | -36.60 | -42.67 | -31.07 | -27.26 | -27.67 | -38.39 | -48.64 | -57.29 | -61.39 | -40.62 | -22.82 | -2.81 | 12.36 | 2.66 | 3.18 | 2.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
8.00 | 10.07 | 9.56 | 10.09 | 9.13 | 6.90 | 3.83 | 0.14 | -0.54 | -3.07 | -4.75 | -7.45 | -12.28 | -22.02 | -21.10 | -28.69 | -25.99 | -31.42 | -22.91 | -27.06 | -20.52 | -18.52 | -18.91 | -23.47 | -27.99 | -31.13 | -31.86 | -41.25 | -45.50 | -51.27 | -56.35 | -12.11 | -14.51 | -11.63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
25.33 | 31.05 | 28.36 | 30.23 | 30.26 | 26.55 | 16.24 | -6.16 | -8.65 | -16.33 | -24.11 | -27.07 | -23.80 | -38.81 | -37.73 | -52.65 | -60.79 | -48.32 | -32.68 | -38.35 | -27.86 | -24.34 | -25.40 | -35.63 | -44.44 | -50.98 | -54.17 | -34.95 | -19.65 | -2.87 | 10.53 | 2.05 | 2.68 | 2.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.6 | 1.5 | 1.8 | 1.6 | 1.6 | 1.5 | 1.4 | 1.4 | 1.3 | 1.3 | 1.2 | 1.2 | 1.3 | 3.0 | 3.1 | 3.2 | - | 1.9 | 2.0 | 2.5 | 2.7 | 3.0 | 3.2 | 3.2 | 3.2 | 3.2 | 2.1 | 2.1 | 2.1 | 2.1 | 0.9 | 0.9 | 0.9 | 0.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
46.8 | 45.9 | - | 58.9 | 71.6 | 76.2 | - | 71.8 | 65.1 | 68.5 | - | 74.3 | 74.9 | 72.7 | - | 39.1 | 26.1 | 50.7 | - | 88.5 | 76.3 | 92.2 | 82.1 | 88.3 | 184.7 | 81.3 | 98.8 | 83.1 | 105.6 | 97.5 | 88.5 | 77.7 | 107.6 | 62.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
61.8 | 61.9 | - | 64.2 | 61.7 | 74.2 | - | 96.0 | 98.5 | 114.8 | - | 123.8 | 158.2 | 159.0 | - | 112.0 | 123.6 | 381.5 | - | 796.4 | 438.7 | 483.4 | - | 530.4 | 734.8 | 395.6 | - | 342.4 | 438.7 | 444.6 | - | 443.9 | 487.6 | 265.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
14.3 | 13.5 | - | 16.7 | 15.1 | 17.2 | - | 24.9 | 22.5 | 27.1 | - | 35.2 | 33.0 | 27.4 | - | 18.6 | 21.7 | 115.8 | - | 144.9 | 65.0 | 50.8 | - | 53.6 | 74.3 | 144.4 | - | 221.2 | 283.4 | 259.6 | - | 225.8 | 248.1 | 135.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 107.8 | - | - | 133.3 | 150.4 | - | 167.8 | 163.6 | 183.3 | - | 198.1 | 233.1 | 231.7 | - | 151.1 | 149.6 | 432.2 | - | 884.9 | 515.0 | 575.6 | 82.1 | 618.8 | 919.5 | 476.9 | 98.8 | 425.5 | 544.3 | 542.1 | 88.5 | 521.6 | 595.2 | 327.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 94.4 | - | - | 118.2 | 133.2 | - | 142.9 | 141.0 | 156.2 | - | 162.9 | 200.1 | 204.3 | - | 132.6 | 128.0 | 316.4 | - | 740.1 | 450.0 | 524.9 | 82.1 | 565.2 | 845.2 | 332.5 | 98.8 | 204.2 | 260.9 | 282.5 | 88.5 | 295.7 | 347.1 | 192.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company TransMedics Group, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Britain
Israel
Canada
China
